CD274 and neoplasm: In order to enhance the clinical benefits of PD‐1/PD‐L1 blockade immunotherapy, further in‐depth investigation of the mechanisms underlying anti‐tumour immunity, clinical response and resistance to the therapy is therefore urgently needed.